Home/Pipeline/Hypoimmune Engineered Cells

Hypoimmune Engineered Cells

Regenerative Medicine (e.g., Type 1 Diabetes)

PreclinicalActive Discovery/Research

Key Facts

Indication
Regenerative Medicine (e.g., Type 1 Diabetes)
Phase
Preclinical
Status
Active Discovery/Research
Company

About Eterna Therapeutics

Eterna Therapeutics is focused on developing transformative mRNA-based cell engineering technologies to create a new generation of cellular medicines. The company's core platform enables precise, in vivo cell reprogramming and gene editing to treat a range of serious diseases. As a publicly traded entity, Eterna is advancing multiple preclinical programs while exploring strategic partnerships to accelerate its pipeline development.

View full company profile